 Kristine Erlandson
Concepts (492)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 200 | 2026 | 3154 | 30.960 |
Why?
| | Frailty | 37 | 2026 | 198 | 13.890 |
Why?
| | Aging | 51 | 2026 | 1966 | 7.210 |
Why?
| | Sarcopenia | 13 | 2026 | 91 | 5.180 |
Why?
| | Exercise | 27 | 2026 | 2201 | 5.080 |
Why?
| | Anti-HIV Agents | 27 | 2026 | 888 | 4.290 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2026 | 439 | 4.090 |
Why?
| | HIV Integrase Inhibitors | 10 | 2026 | 78 | 3.940 |
Why?
| | Anti-Retroviral Agents | 16 | 2025 | 250 | 3.830 |
Why?
| | Antiretroviral Therapy, Highly Active | 15 | 2021 | 278 | 3.740 |
Why?
| | Middle Aged | 145 | 2026 | 35875 | 3.450 |
Why?
| | Exercise Therapy | 9 | 2026 | 473 | 3.330 |
Why?
| | Muscle, Skeletal | 14 | 2025 | 1795 | 3.290 |
Why?
| | Body Composition | 16 | 2026 | 706 | 3.270 |
Why?
| | Aged | 98 | 2026 | 25913 | 2.870 |
Why?
| | Accidental Falls | 12 | 2026 | 222 | 2.860 |
Why?
| | HIV-1 | 18 | 2024 | 896 | 2.860 |
Why?
| | Male | 168 | 2026 | 72315 | 2.780 |
Why?
| | Osteoporosis | 7 | 2025 | 236 | 2.760 |
Why?
| | Quinolines | 4 | 2026 | 193 | 2.640 |
Why?
| | Humans | 241 | 2026 | 144759 | 2.640 |
Why?
| | Inflammation | 20 | 2026 | 2878 | 2.610 |
Why?
| | Hand Strength | 9 | 2026 | 144 | 2.460 |
Why?
| | Cytomegalovirus Infections | 6 | 2026 | 206 | 2.400 |
Why?
| | Glucagon-Like Peptides | 3 | 2026 | 70 | 2.400 |
Why?
| | Acquired Immunodeficiency Syndrome | 6 | 2023 | 235 | 2.390 |
Why?
| | Walking Speed | 8 | 2025 | 51 | 2.250 |
Why?
| | Female | 142 | 2026 | 78271 | 2.230 |
Why?
| | Cardiovascular Diseases | 17 | 2026 | 2168 | 2.230 |
Why?
| | Weight Gain | 11 | 2026 | 556 | 2.150 |
Why?
| | Healthy Aging | 4 | 2025 | 40 | 2.100 |
Why?
| | Cohort Studies | 38 | 2026 | 5960 | 2.040 |
Why?
| | Adult | 101 | 2026 | 40449 | 2.020 |
Why?
| | Bone Density | 6 | 2025 | 482 | 1.890 |
Why?
| | Growth Hormone-Releasing Hormone | 4 | 2026 | 19 | 1.810 |
Why?
| | Adipose Tissue | 7 | 2020 | 652 | 1.810 |
Why?
| | Risk Factors | 39 | 2026 | 10779 | 1.650 |
Why?
| | High-Intensity Interval Training | 4 | 2026 | 46 | 1.550 |
Why?
| | Absorptiometry, Photon | 9 | 2026 | 276 | 1.520 |
Why?
| | Quality of Life | 16 | 2026 | 3185 | 1.490 |
Why?
| | Fatty Liver | 2 | 2025 | 251 | 1.410 |
Why?
| | Biomarkers | 19 | 2026 | 4271 | 1.410 |
Why?
| | HIV | 14 | 2023 | 250 | 1.400 |
Why?
| | Tenofovir | 6 | 2026 | 295 | 1.340 |
Why?
| | Lipopolysaccharide Receptors | 4 | 2022 | 87 | 1.290 |
Why?
| | Hospitalization | 7 | 2026 | 2433 | 1.230 |
Why?
| | Frail Elderly | 9 | 2026 | 134 | 1.200 |
Why?
| | Pyridones | 3 | 2026 | 199 | 1.130 |
Why?
| | Obesity, Abdominal | 2 | 2019 | 46 | 1.120 |
Why?
| | Diabetes Mellitus | 6 | 2024 | 1098 | 1.110 |
Why?
| | Cross-Sectional Studies | 27 | 2025 | 5868 | 1.090 |
Why?
| | Disease Management | 5 | 2020 | 645 | 1.070 |
Why?
| | Cognitive Dysfunction | 4 | 2025 | 461 | 1.060 |
Why?
| | Comorbidity | 17 | 2024 | 1658 | 1.060 |
Why?
| | Activities of Daily Living | 5 | 2023 | 441 | 1.060 |
Why?
| | Rosuvastatin Calcium | 3 | 2015 | 21 | 1.040 |
Why?
| | Fractures, Bone | 4 | 2024 | 414 | 1.020 |
Why?
| | Cognition | 6 | 2026 | 1266 | 1.020 |
Why?
| | Muscles | 4 | 2024 | 333 | 0.990 |
Why?
| | Mass Screening | 2 | 2025 | 1347 | 0.980 |
Why?
| | Bone and Bones | 3 | 2026 | 314 | 0.970 |
Why?
| | Longitudinal Studies | 16 | 2026 | 2947 | 0.960 |
Why?
| | Prospective Studies | 24 | 2025 | 7990 | 0.940 |
Why?
| | Plaque, Atherosclerotic | 2 | 2023 | 60 | 0.940 |
Why?
| | Adiposity | 4 | 2019 | 543 | 0.910 |
Why?
| | Body Mass Index | 11 | 2026 | 2438 | 0.900 |
Why?
| | Psoas Muscles | 1 | 2025 | 14 | 0.890 |
Why?
| | Aged, 80 and over | 19 | 2026 | 8265 | 0.890 |
Why?
| | Self Efficacy | 4 | 2024 | 414 | 0.860 |
Why?
| | Metabolic Diseases | 2 | 2023 | 114 | 0.850 |
Why?
| | Alanine | 2 | 2026 | 171 | 0.840 |
Why?
| | DNA, Mitochondrial | 3 | 2021 | 211 | 0.840 |
Why?
| | Muscle Strength | 4 | 2022 | 330 | 0.830 |
Why?
| | Gastrointestinal Microbiome | 3 | 2025 | 771 | 0.830 |
Why?
| | Cytomegalovirus | 6 | 2026 | 168 | 0.810 |
Why?
| | HIV Long-Term Survivors | 2 | 2020 | 3 | 0.810 |
Why?
| | Advance Care Planning | 3 | 2021 | 243 | 0.800 |
Why?
| | Motor Activity | 4 | 2016 | 721 | 0.800 |
Why?
| | Cigarette Smoking | 1 | 2025 | 99 | 0.800 |
Why?
| | Physical Fitness | 2 | 2015 | 209 | 0.790 |
Why?
| | HIV Seropositivity | 5 | 2024 | 119 | 0.780 |
Why?
| | Neurocognitive Disorders | 3 | 2019 | 33 | 0.780 |
Why?
| | HIV Integrase | 1 | 2024 | 74 | 0.770 |
Why?
| | Telemedicine | 2 | 2023 | 945 | 0.760 |
Why?
| | CD4 Lymphocyte Count | 7 | 2020 | 277 | 0.760 |
Why?
| | Coronary Artery Disease | 3 | 2023 | 741 | 0.750 |
Why?
| | Body Weight | 3 | 2016 | 976 | 0.740 |
Why?
| | Advance Directives | 2 | 2021 | 87 | 0.720 |
Why?
| | Telerehabilitation | 1 | 2022 | 43 | 0.710 |
Why?
| | Malnutrition | 1 | 2023 | 86 | 0.700 |
Why?
| | Obesity | 6 | 2026 | 3077 | 0.700 |
Why?
| | Organ Transplantation | 1 | 2024 | 247 | 0.680 |
Why?
| | Double-Blind Method | 6 | 2026 | 2029 | 0.680 |
Why?
| | Lipodystrophy | 2 | 2023 | 14 | 0.670 |
Why?
| | Atazanavir Sulfate | 2 | 2020 | 42 | 0.670 |
Why?
| | Geriatric Assessment | 5 | 2026 | 233 | 0.660 |
Why?
| | United States | 23 | 2026 | 15966 | 0.660 |
Why?
| | Raltegravir Potassium | 1 | 2020 | 18 | 0.650 |
Why?
| | Odds Ratio | 8 | 2022 | 1075 | 0.650 |
Why?
| | Guideline Adherence | 1 | 2025 | 589 | 0.650 |
Why?
| | Darunavir | 1 | 2020 | 20 | 0.650 |
Why?
| | Heart Rate | 1 | 2024 | 855 | 0.640 |
Why?
| | Hyperlipidemias | 1 | 2021 | 122 | 0.630 |
Why?
| | Vaccination Coverage | 2 | 2018 | 103 | 0.630 |
Why?
| | Metabolic Syndrome | 1 | 2024 | 354 | 0.630 |
Why?
| | Depression | 3 | 2025 | 1558 | 0.630 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 121 | 0.620 |
Why?
| | Occupational Therapy | 1 | 2022 | 111 | 0.620 |
Why?
| | Prevalence | 13 | 2026 | 2834 | 0.620 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2024 | 266 | 0.610 |
Why?
| | Placebos | 5 | 2025 | 192 | 0.610 |
Why?
| | Mobile Applications | 1 | 2022 | 196 | 0.600 |
Why?
| | HIV-Associated Lipodystrophy Syndrome | 3 | 2019 | 11 | 0.600 |
Why?
| | Herpes Zoster Vaccine | 2 | 2018 | 154 | 0.590 |
Why?
| | Triazoles | 3 | 2026 | 184 | 0.590 |
Why?
| | Viral Load | 7 | 2024 | 526 | 0.590 |
Why?
| | Interleukin-10 | 1 | 2021 | 309 | 0.590 |
Why?
| | Haplotypes | 2 | 2020 | 490 | 0.580 |
Why?
| | Sex Factors | 5 | 2025 | 2112 | 0.560 |
Why?
| | Health Promotion | 1 | 2024 | 774 | 0.550 |
Why?
| | Retrospective Studies | 17 | 2025 | 17066 | 0.550 |
Why?
| | Herpes Zoster | 2 | 2018 | 315 | 0.530 |
Why?
| | Guidelines as Topic | 2 | 2019 | 267 | 0.530 |
Why?
| | Lymphocyte Activation | 3 | 2017 | 1126 | 0.530 |
Why?
| | Plague | 2 | 2015 | 60 | 0.530 |
Why?
| | Sexual and Gender Minorities | 2 | 2021 | 251 | 0.530 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2017 | 319 | 0.520 |
Why?
| | Immunosenescence | 1 | 2017 | 5 | 0.510 |
Why?
| | Lung | 4 | 2026 | 4109 | 0.510 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2017 | 114 | 0.510 |
Why?
| | Logistic Models | 6 | 2025 | 2117 | 0.500 |
Why?
| | Sleep Wake Disorders | 1 | 2020 | 301 | 0.490 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2023 | 24 | 0.490 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 221 | 0.490 |
Why?
| | Antibodies, Viral | 2 | 2024 | 672 | 0.490 |
Why?
| | Academic Medical Centers | 1 | 2019 | 547 | 0.480 |
Why?
| | Hormones | 1 | 2017 | 134 | 0.480 |
Why?
| | HIV Wasting Syndrome | 1 | 2016 | 3 | 0.480 |
Why?
| | Yersinia pestis | 2 | 2015 | 45 | 0.460 |
Why?
| | Attitude to Health | 1 | 2019 | 436 | 0.460 |
Why?
| | Age Factors | 12 | 2026 | 3333 | 0.460 |
Why?
| | RNA, Viral | 3 | 2019 | 688 | 0.450 |
Why?
| | Muscular Atrophy | 1 | 2016 | 89 | 0.450 |
Why?
| | Fluorobenzenes | 1 | 2015 | 17 | 0.440 |
Why?
| | Integrases | 4 | 2024 | 122 | 0.440 |
Why?
| | Monocytes | 2 | 2015 | 538 | 0.440 |
Why?
| | Biomedical Research | 4 | 2024 | 710 | 0.440 |
Why?
| | Cannabis | 2 | 2023 | 509 | 0.440 |
Why?
| | Weight Loss | 4 | 2026 | 836 | 0.430 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2015 | 142 | 0.430 |
Why?
| | Plasma | 2 | 2018 | 225 | 0.420 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.420 |
Why?
| | Intraabdominal Infections | 1 | 2014 | 12 | 0.420 |
Why?
| | Orchitis | 1 | 2014 | 5 | 0.420 |
Why?
| | Penicillin G | 1 | 2014 | 7 | 0.420 |
Why?
| | Adipocytes | 1 | 2016 | 223 | 0.420 |
Why?
| | Pilot Projects | 5 | 2026 | 1886 | 0.410 |
Why?
| | Anticholesteremic Agents | 1 | 2015 | 152 | 0.410 |
Why?
| | Syphilis | 1 | 2014 | 33 | 0.400 |
Why?
| | Polypharmacy | 3 | 2024 | 93 | 0.400 |
Why?
| | Tomography, X-Ray Computed | 5 | 2025 | 2730 | 0.400 |
Why?
| | Sarcoma, Kaposi | 1 | 2014 | 83 | 0.390 |
Why?
| | Mycoses | 1 | 2014 | 88 | 0.390 |
Why?
| | Motivation | 4 | 2024 | 610 | 0.390 |
Why?
| | Decision Making | 1 | 2021 | 975 | 0.390 |
Why?
| | Retinal Detachment | 1 | 2014 | 72 | 0.390 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2014 | 130 | 0.390 |
Why?
| | Microbiota | 1 | 2021 | 781 | 0.390 |
Why?
| | Self Report | 5 | 2022 | 872 | 0.380 |
Why?
| | Adenine | 2 | 2026 | 339 | 0.380 |
Why?
| | Incidence | 6 | 2026 | 2879 | 0.370 |
Why?
| | Coinfection | 3 | 2021 | 141 | 0.370 |
Why?
| | Transplant Recipients | 2 | 2024 | 180 | 0.370 |
Why?
| | Vitamin D Deficiency | 1 | 2014 | 186 | 0.360 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2026 | 1720 | 0.360 |
Why?
| | Marijuana Smoking | 1 | 2015 | 250 | 0.350 |
Why?
| | Pyrimidines | 1 | 2015 | 532 | 0.330 |
Why?
| | Pandemics | 4 | 2023 | 1694 | 0.330 |
Why?
| | Benzoxazines | 3 | 2023 | 31 | 0.330 |
Why?
| | Sulfonamides | 1 | 2015 | 580 | 0.330 |
Why?
| | Cyclopropanes | 3 | 2023 | 83 | 0.330 |
Why?
| | Lamivudine | 3 | 2017 | 65 | 0.330 |
Why?
| | Vitamin D | 1 | 2014 | 400 | 0.320 |
Why?
| | Alkynes | 3 | 2023 | 66 | 0.320 |
Why?
| | Anti-Bacterial Agents | 2 | 2014 | 1907 | 0.320 |
Why?
| | Atherosclerosis | 2 | 2025 | 409 | 0.320 |
Why?
| | Mental Health | 3 | 2024 | 790 | 0.320 |
Why?
| | Metformin | 2 | 2024 | 318 | 0.310 |
Why?
| | Epigenesis, Genetic | 2 | 2026 | 684 | 0.310 |
Why?
| | Colorado | 7 | 2024 | 4564 | 0.300 |
Why?
| | Muscle Weakness | 2 | 2020 | 92 | 0.300 |
Why?
| | Survival Analysis | 4 | 2025 | 1382 | 0.300 |
Why?
| | Veterans | 4 | 2023 | 1603 | 0.300 |
Why?
| | Proportional Hazards Models | 4 | 2026 | 1325 | 0.300 |
Why?
| | Subcutaneous Fat | 5 | 2021 | 78 | 0.300 |
Why?
| | Case-Control Studies | 4 | 2019 | 3604 | 0.290 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2026 | 917 | 0.290 |
Why?
| | Disease Progression | 4 | 2024 | 2847 | 0.290 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2026 | 1129 | 0.280 |
Why?
| | Interleukin-6 | 3 | 2021 | 780 | 0.280 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 2 | 2021 | 81 | 0.280 |
Why?
| | Focus Groups | 3 | 2025 | 573 | 0.270 |
Why?
| | Virginiamycin | 1 | 2008 | 3 | 0.270 |
Why?
| | Energy Metabolism | 1 | 2014 | 935 | 0.270 |
Why?
| | Vancomycin Resistance | 1 | 2008 | 16 | 0.270 |
Why?
| | Emtricitabine | 2 | 2021 | 205 | 0.270 |
Why?
| | Oxazolidinones | 1 | 2008 | 17 | 0.270 |
Why?
| | Immunoglobulin G | 3 | 2024 | 893 | 0.270 |
Why?
| | Enterococcus | 1 | 2008 | 22 | 0.270 |
Why?
| | Canada | 4 | 2025 | 428 | 0.270 |
Why?
| | Treatment Outcome | 9 | 2026 | 11679 | 0.270 |
Why?
| | Acetamides | 1 | 2008 | 37 | 0.260 |
Why?
| | United Kingdom | 3 | 2025 | 338 | 0.260 |
Why?
| | Surveys and Questionnaires | 10 | 2024 | 6048 | 0.260 |
Why?
| | Social Support | 2 | 2024 | 652 | 0.260 |
Why?
| | Multicenter Studies as Topic | 2 | 2026 | 405 | 0.260 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2008 | 69 | 0.250 |
Why?
| | Fatigue | 4 | 2026 | 366 | 0.250 |
Why?
| | Body Fat Distribution | 3 | 2019 | 45 | 0.250 |
Why?
| | Electronic Health Records | 2 | 2025 | 1173 | 0.250 |
Why?
| | Insulin Resistance | 1 | 2015 | 1241 | 0.250 |
Why?
| | Resistance Training | 2 | 2026 | 182 | 0.250 |
Why?
| | Anthropometry | 2 | 2017 | 200 | 0.240 |
Why?
| | Loneliness | 2 | 2024 | 60 | 0.240 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 920 | 0.230 |
Why?
| | Zidovudine | 2 | 2017 | 77 | 0.230 |
Why?
| | Radiography, Abdominal | 2 | 2017 | 44 | 0.230 |
Why?
| | Young Adult | 13 | 2025 | 14105 | 0.230 |
Why?
| | Bacteremia | 1 | 2008 | 221 | 0.220 |
Why?
| | Life Expectancy | 3 | 2020 | 72 | 0.220 |
Why?
| | Risk Assessment | 6 | 2024 | 3671 | 0.220 |
Why?
| | Independent Living | 3 | 2025 | 114 | 0.220 |
Why?
| | Patient Dropouts | 1 | 2025 | 65 | 0.220 |
Why?
| | Forced Expiratory Volume | 1 | 2026 | 449 | 0.220 |
Why?
| | Bone Diseases, Metabolic | 1 | 2025 | 56 | 0.220 |
Why?
| | Hypoglycemic Agents | 2 | 2024 | 1387 | 0.210 |
Why?
| | Aminobutyrates | 1 | 2024 | 31 | 0.210 |
Why?
| | Thigh | 2 | 2022 | 47 | 0.210 |
Why?
| | Seroepidemiologic Studies | 1 | 2024 | 172 | 0.210 |
Why?
| | Respiratory Function Tests | 1 | 2026 | 547 | 0.210 |
Why?
| | Community Participation | 1 | 2025 | 132 | 0.210 |
Why?
| | Substance Abuse, Intravenous | 1 | 2025 | 128 | 0.210 |
Why?
| | Methadone | 1 | 2025 | 121 | 0.210 |
Why?
| | Community-Based Participatory Research | 1 | 2025 | 166 | 0.210 |
Why?
| | Ireland | 4 | 2025 | 32 | 0.200 |
Why?
| | Drug Substitution | 1 | 2024 | 63 | 0.200 |
Why?
| | Disability Evaluation | 3 | 2022 | 310 | 0.200 |
Why?
| | Qualitative Research | 5 | 2025 | 1671 | 0.200 |
Why?
| | Blood Glucose | 1 | 2014 | 2327 | 0.200 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2025 | 146 | 0.200 |
Why?
| | HIV Protease Inhibitors | 2 | 2021 | 69 | 0.200 |
Why?
| | Cost of Illness | 1 | 2026 | 321 | 0.200 |
Why?
| | Chronic Disease | 5 | 2023 | 1813 | 0.190 |
Why?
| | Magnetic Resonance Imaging | 3 | 2025 | 3863 | 0.190 |
Why?
| | Prognosis | 3 | 2021 | 4282 | 0.190 |
Why?
| | Drug Therapy, Combination | 3 | 2021 | 1047 | 0.190 |
Why?
| | Medication Adherence | 2 | 2018 | 539 | 0.190 |
Why?
| | Organizations | 1 | 2022 | 27 | 0.190 |
Why?
| | NF-kappa B | 1 | 2026 | 661 | 0.180 |
Why?
| | Awards and Prizes | 1 | 2023 | 70 | 0.180 |
Why?
| | Propensity Score | 1 | 2024 | 367 | 0.180 |
Why?
| | Self-Management | 1 | 2025 | 201 | 0.180 |
Why?
| | Computed Tomography Angiography | 1 | 2023 | 145 | 0.180 |
Why?
| | DNA Methylation | 2 | 2026 | 681 | 0.180 |
Why?
| | Homosexuality, Male | 2 | 2021 | 222 | 0.180 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2021 | 15 | 0.170 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2021 | 40 | 0.170 |
Why?
| | Coronary Vessels | 1 | 2023 | 251 | 0.170 |
Why?
| | Coronary Angiography | 1 | 2023 | 323 | 0.170 |
Why?
| | Citrate (si)-Synthase | 1 | 2021 | 57 | 0.170 |
Why?
| | Substance-Related Disorders | 2 | 2022 | 1094 | 0.170 |
Why?
| | Succinic Acid | 1 | 2021 | 42 | 0.170 |
Why?
| | Counseling | 1 | 2024 | 408 | 0.170 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 41 | 0.170 |
Why?
| | Postural Balance | 1 | 2024 | 240 | 0.170 |
Why?
| | Isoniazid | 1 | 2021 | 71 | 0.170 |
Why?
| | Immunity | 1 | 2022 | 139 | 0.170 |
Why?
| | North America | 1 | 2022 | 310 | 0.170 |
Why?
| | Prediabetic State | 1 | 2024 | 245 | 0.170 |
Why?
| | Smoking Cessation | 1 | 2025 | 439 | 0.170 |
Why?
| | Sequence Alignment | 1 | 2021 | 366 | 0.170 |
Why?
| | Latent Tuberculosis | 1 | 2021 | 71 | 0.160 |
Why?
| | Italy | 1 | 2020 | 113 | 0.160 |
Why?
| | Immune System | 1 | 2021 | 179 | 0.160 |
Why?
| | Epidemics | 1 | 2021 | 98 | 0.160 |
Why?
| | Program Evaluation | 1 | 2024 | 948 | 0.160 |
Why?
| | Opioid-Related Disorders | 2 | 2025 | 600 | 0.160 |
Why?
| | Feces | 2 | 2025 | 513 | 0.160 |
Why?
| | Hospitals, Teaching | 1 | 2020 | 119 | 0.160 |
Why?
| | Death | 1 | 2021 | 130 | 0.160 |
Why?
| | Socioeconomic Factors | 2 | 2016 | 1326 | 0.160 |
Why?
| | Kidney Failure, Chronic | 2 | 2017 | 598 | 0.150 |
Why?
| | Actigraphy | 1 | 2020 | 145 | 0.150 |
Why?
| | Energy Intake | 1 | 2022 | 499 | 0.150 |
Why?
| | Self Care | 2 | 2021 | 389 | 0.150 |
Why?
| | Lipoproteins, LDL | 2 | 2022 | 119 | 0.150 |
Why?
| | Superoxide Dismutase | 1 | 2021 | 301 | 0.150 |
Why?
| | Cause of Death | 2 | 2019 | 471 | 0.150 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 488 | 0.150 |
Why?
| | C-Reactive Protein | 1 | 2021 | 416 | 0.150 |
Why?
| | Respiratory Insufficiency | 1 | 2023 | 326 | 0.150 |
Why?
| | Blood Pressure | 1 | 2026 | 1769 | 0.150 |
Why?
| | Bone Diseases | 1 | 2019 | 61 | 0.150 |
Why?
| | Psychotropic Drugs | 1 | 2019 | 77 | 0.140 |
Why?
| | Waist Circumference | 1 | 2019 | 139 | 0.140 |
Why?
| | Lumbar Vertebrae | 2 | 2018 | 252 | 0.140 |
Why?
| | Fatty Acids, Volatile | 1 | 2019 | 60 | 0.140 |
Why?
| | Survivors | 1 | 2022 | 520 | 0.140 |
Why?
| | Preventive Health Services | 1 | 2020 | 152 | 0.140 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 226 | 0.130 |
Why?
| | Metagenome | 1 | 2019 | 149 | 0.130 |
Why?
| | Feasibility Studies | 1 | 2022 | 1095 | 0.130 |
Why?
| | Zimbabwe | 2 | 2016 | 76 | 0.130 |
Why?
| | Femur Head | 1 | 2018 | 39 | 0.130 |
Why?
| | Sustained Virologic Response | 1 | 2018 | 46 | 0.130 |
Why?
| | Inpatients | 1 | 2022 | 545 | 0.130 |
Why?
| | Metagenomics | 1 | 2019 | 181 | 0.130 |
Why?
| | Dysbiosis | 1 | 2019 | 187 | 0.130 |
Why?
| | Adaptation, Physiological | 1 | 2021 | 570 | 0.130 |
Why?
| | Healthy Volunteers | 1 | 2018 | 215 | 0.130 |
Why?
| | Gait | 1 | 2020 | 313 | 0.130 |
Why?
| | Diagnostic Errors | 2 | 2015 | 175 | 0.130 |
Why?
| | Movement | 1 | 2019 | 293 | 0.130 |
Why?
| | Dogs | 2 | 2015 | 437 | 0.130 |
Why?
| | Phenotype | 3 | 2026 | 3162 | 0.130 |
Why?
| | Alcohol Drinking | 1 | 2024 | 826 | 0.130 |
Why?
| | Drug Discovery | 1 | 2018 | 155 | 0.120 |
Why?
| | Memory, Short-Term | 1 | 2019 | 271 | 0.120 |
Why?
| | Glucose | 1 | 2022 | 1047 | 0.120 |
Why?
| | Disease Susceptibility | 1 | 2018 | 348 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1217 | 0.120 |
Why?
| | Drug Combinations | 1 | 2017 | 390 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2023 | 947 | 0.120 |
Why?
| | Referral and Consultation | 1 | 2022 | 851 | 0.120 |
Why?
| | Attention | 1 | 2019 | 457 | 0.110 |
Why?
| | Machine Learning | 1 | 2021 | 585 | 0.110 |
Why?
| | Human Activities | 1 | 2015 | 20 | 0.110 |
Why?
| | Disease Vectors | 1 | 2015 | 15 | 0.110 |
Why?
| | Adolescent | 7 | 2025 | 22428 | 0.110 |
Why?
| | Myalgia | 1 | 2015 | 13 | 0.110 |
Why?
| | Pseudomonas | 1 | 2015 | 33 | 0.110 |
Why?
| | Gait Disorders, Neurologic | 1 | 2015 | 45 | 0.110 |
Why?
| | Diet | 2 | 2022 | 1273 | 0.110 |
Why?
| | Puerto Rico | 2 | 2025 | 58 | 0.110 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 865 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2115 | 0.110 |
Why?
| | Dog Diseases | 1 | 2015 | 70 | 0.110 |
Why?
| | Dideoxynucleosides | 1 | 2014 | 22 | 0.110 |
Why?
| | Genetic Markers | 1 | 2015 | 331 | 0.100 |
Why?
| | Microbiological Techniques | 1 | 2014 | 33 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 1 | 2018 | 474 | 0.100 |
Why?
| | Recurrence | 1 | 2017 | 1135 | 0.100 |
Why?
| | Ophthalmoscopy | 1 | 2014 | 38 | 0.100 |
Why?
| | Pneumonia, Bacterial | 1 | 2015 | 113 | 0.100 |
Why?
| | Computational Biology | 1 | 2019 | 680 | 0.100 |
Why?
| | Herpesvirus 8, Human | 1 | 2014 | 68 | 0.100 |
Why?
| | Fever | 1 | 2015 | 311 | 0.100 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 32 | 0.100 |
Why?
| | Aging, Premature | 1 | 2013 | 16 | 0.100 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2013 | 43 | 0.100 |
Why?
| | Antifungal Agents | 1 | 2014 | 149 | 0.100 |
Why?
| | Dyspnea | 1 | 2015 | 251 | 0.100 |
Why?
| | Genetic Variation | 1 | 2018 | 983 | 0.100 |
Why?
| | Health Status Disparities | 1 | 2016 | 321 | 0.100 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 129 | 0.100 |
Why?
| | Lopinavir | 1 | 2013 | 30 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 851 | 0.100 |
Why?
| | Radiography | 1 | 2015 | 844 | 0.090 |
Why?
| | Peritoneal Dialysis | 1 | 2014 | 100 | 0.090 |
Why?
| | Neoplasms | 2 | 2019 | 2875 | 0.090 |
Why?
| | Regression Analysis | 1 | 2015 | 1003 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2015 | 427 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2018 | 767 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2012 | 333 | 0.090 |
Why?
| | Oligopeptides | 1 | 2013 | 269 | 0.080 |
Why?
| | Outpatients | 1 | 2014 | 442 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1489 | 0.080 |
Why?
| | Visual Acuity | 1 | 2014 | 489 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2016 | 5408 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1980 | 0.080 |
Why?
| | Pregnancy | 1 | 2023 | 7190 | 0.080 |
Why?
| | Membrane Glycoproteins | 1 | 2013 | 496 | 0.080 |
Why?
| | Mental Disorders | 1 | 2019 | 1168 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2024 | 2583 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2018 | 1098 | 0.080 |
Why?
| | Research Design | 2 | 2025 | 1135 | 0.070 |
Why?
| | Pyridines | 1 | 2013 | 605 | 0.070 |
Why?
| | Interviews as Topic | 2 | 2024 | 901 | 0.070 |
Why?
| | Congresses as Topic | 2 | 2019 | 221 | 0.070 |
Why?
| | Linezolid | 1 | 2008 | 25 | 0.070 |
Why?
| | Animals | 3 | 2021 | 38058 | 0.060 |
Why?
| | Baltimore | 1 | 2025 | 71 | 0.060 |
Why?
| | Quality-Adjusted Life Years | 1 | 2026 | 121 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3409 | 0.050 |
Why?
| | Missouri | 1 | 2024 | 66 | 0.050 |
Why?
| | Mortality | 2 | 2019 | 375 | 0.050 |
Why?
| | Bias | 1 | 2025 | 202 | 0.050 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2023 | 9 | 0.050 |
Why?
| | Registries | 2 | 2024 | 2385 | 0.050 |
Why?
| | Ohio | 1 | 2023 | 145 | 0.050 |
Why?
| | Data Interpretation, Statistical | 1 | 2025 | 372 | 0.050 |
Why?
| | Financing, Organized | 1 | 2023 | 36 | 0.050 |
Why?
| | Opiate Substitution Treatment | 1 | 2025 | 187 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2026 | 573 | 0.050 |
Why?
| | Intention | 1 | 2024 | 183 | 0.050 |
Why?
| | Nucleosides | 1 | 2022 | 25 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2025 | 558 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2023 | 140 | 0.050 |
Why?
| | Global Burden of Disease | 1 | 2022 | 23 | 0.050 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2022 | 87 | 0.050 |
Why?
| | Pharmacogenetics | 1 | 2023 | 172 | 0.050 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2023 | 126 | 0.050 |
Why?
| | Cocaine | 1 | 2024 | 160 | 0.050 |
Why?
| | Faculty | 1 | 2023 | 149 | 0.040 |
Why?
| | Concept Formation | 1 | 2022 | 36 | 0.040 |
Why?
| | Hypnotics and Sedatives | 1 | 2024 | 216 | 0.040 |
Why?
| | Habits | 1 | 2022 | 52 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 257 | 0.040 |
Why?
| | Citric Acid | 1 | 2021 | 34 | 0.040 |
Why?
| | Rifampin | 1 | 2021 | 82 | 0.040 |
Why?
| | Hematopoiesis | 1 | 2022 | 194 | 0.040 |
Why?
| | Residence Characteristics | 1 | 2024 | 377 | 0.040 |
Why?
| | Mentors | 1 | 2023 | 219 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2027 | 0.040 |
Why?
| | Computer Simulation | 1 | 2025 | 1025 | 0.040 |
Why?
| | New York City | 1 | 2020 | 89 | 0.040 |
Why?
| | Intra-Abdominal Fat | 1 | 2021 | 100 | 0.040 |
Why?
| | Heart Failure | 1 | 2014 | 2323 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2025 | 1134 | 0.040 |
Why?
| | Particulate Matter | 1 | 2023 | 347 | 0.040 |
Why?
| | Europe | 1 | 2021 | 412 | 0.040 |
Why?
| | Mobility Limitation | 1 | 2020 | 66 | 0.040 |
Why?
| | Marijuana Use | 1 | 2023 | 213 | 0.040 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2019 | 15 | 0.040 |
Why?
| | Protective Factors | 1 | 2020 | 99 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 779 | 0.040 |
Why?
| | Antitubercular Agents | 1 | 2021 | 215 | 0.040 |
Why?
| | Hip Fractures | 1 | 2020 | 84 | 0.040 |
Why?
| | Cardiorespiratory Fitness | 1 | 2020 | 72 | 0.040 |
Why?
| | Health Behavior | 1 | 2024 | 785 | 0.040 |
Why?
| | Demography | 1 | 2019 | 288 | 0.040 |
Why?
| | Drug Utilization | 1 | 2019 | 166 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2019 | 83 | 0.040 |
Why?
| | Geriatrics | 1 | 2019 | 96 | 0.030 |
Why?
| | Bacteria | 1 | 2025 | 889 | 0.030 |
Why?
| | AIDS-Associated Nephropathy | 1 | 2018 | 7 | 0.030 |
Why?
| | Chemistry Techniques, Analytical | 1 | 2018 | 20 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 488 | 0.030 |
Why?
| | Organ Size | 1 | 2019 | 463 | 0.030 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 114 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2023 | 1030 | 0.030 |
Why?
| | AIDS Dementia Complex | 1 | 2018 | 52 | 0.030 |
Why?
| | Diabetes Complications | 1 | 2019 | 222 | 0.030 |
Why?
| | Psychometrics | 1 | 2022 | 734 | 0.030 |
Why?
| | Models, Statistical | 1 | 2022 | 681 | 0.030 |
Why?
| | Hair | 1 | 2018 | 88 | 0.030 |
Why?
| | Blood Chemical Analysis | 1 | 2018 | 109 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2023 | 790 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 885 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3890 | 0.030 |
Why?
| | RNA | 1 | 2023 | 940 | 0.030 |
Why?
| | Enzymes | 1 | 2017 | 65 | 0.030 |
Why?
| | Haiti | 1 | 2016 | 14 | 0.030 |
Why?
| | Thailand | 1 | 2016 | 18 | 0.030 |
Why?
| | Menopause | 1 | 2019 | 320 | 0.030 |
Why?
| | Critical Illness | 1 | 2023 | 891 | 0.030 |
Why?
| | Research | 1 | 2019 | 431 | 0.030 |
Why?
| | Malawi | 1 | 2016 | 57 | 0.030 |
Why?
| | Peru | 1 | 2016 | 62 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1075 | 0.030 |
Why?
| | Creatinine | 1 | 2018 | 506 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 417 | 0.030 |
Why?
| | Brazil | 1 | 2016 | 180 | 0.030 |
Why?
| | India | 1 | 2016 | 218 | 0.030 |
Why?
| | Public Health | 1 | 2020 | 566 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 1143 | 0.030 |
Why?
| | Time Factors | 1 | 2026 | 7173 | 0.030 |
Why?
| | South Africa | 1 | 2016 | 261 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1539 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 627 | 0.030 |
Why?
| | Wisconsin | 1 | 2014 | 99 | 0.030 |
Why?
| | Health Status | 1 | 2020 | 836 | 0.030 |
Why?
| | Pelvic Bones | 1 | 2016 | 135 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2017 | 527 | 0.020 |
Why?
| | Morbidity | 1 | 2014 | 323 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2015 | 422 | 0.020 |
Why?
| | Drug Interactions | 1 | 2013 | 398 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 4089 | 0.020 |
Why?
| | Hypertension | 1 | 2019 | 1263 | 0.020 |
Why?
| | Brain | 1 | 2021 | 2933 | 0.020 |
Why?
| | Kidney | 1 | 2013 | 1495 | 0.010 |
Why?
| | Liver | 1 | 2013 | 1887 | 0.010 |
Why?
|
|
Erlandson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|